Baseline characteristics (unadjusted) of the Norwegian and New Zealand participants. Participants free of prior CVD.
| Men | Women | |||
| European | Indian | European | Indian | |
| New Zealand cohort | ||||
| N | 63 319 | 9997 | 49 094 | 7039 |
| Age (years) | 55.0 (9.3) | 47.4 (9.7) | 58.7 (8.7) | 52.9 (8.5) |
| Age range | 30.0–74.0 | 30.0–74.0 | 30.0–74.0 | 30.0–74.0 |
| TC (mmol/L) | 5.36 (1.1) | 5.09 (1.1) | 5.68 (1.1) | 5.04 (1.0) |
| HDL cholesterol (mmol/L | 1.29 (0.4) | 1.14 (0.3) | 1.59 (0.5) | 1.30 (0.3) |
| LDL cholesterol (mmol/L) | 3.3 (1.0) | 2.9 (1.0) | 3.4 (1.1) | 2.8 (0.9) |
| TC/HDL ratio | 4.35 (1.3) | 4.60 (1.3) | 3.68 (1.1) | 3.93 (1.1) |
| SBP (mm Hg) | 131.5 (16.3) | 125.3 (16.1) | 131.6 (17.4) | 126.1 (17.4) |
| Diastolic blood pressure (mm Hg) | 80.5 (10.0) | 79.1 (10.4) | 78.8 (9.7) | 77.4 (9.8) |
| Hypertension* (%) | 40 | 34 | 44 | 39 |
| Type 2 diabetes† (%) | 9 | 24 | 9 | 29 |
| Former smokers (%) | 19 | 6 | 16 | 1 |
| Current smokers (%) | 12 | 9 | 10 | 1 |
| Family history of CVD‡ (%) | 12 | 8 | 15 | 10 |
| Antihypertensive treatment (%) | 24 | 26 | 30 | 32 |
| Lipid-lowering treatment (%) | 18 | 27 | 18 | 27 |
| Follow-up time (years) | 2.94 (2.3) | 2.93 (2.0) | 2.92 (2.3) | 2.83 (1.9) |